Overview

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

Status:
Not yet recruiting

Trial end date:
2031-01-01

Target enrollment:

Participant gender:

Summary

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.

Phase:

Phase 3

Details

Lead Sponsor:

Gilead Sciences

Collaborator:

Alliance Foundation Trials, LLC.

Treatments:

Capecitabine
Pembrolizumab